Therapeutics News and Research

RSS

UTHSC's drug candidate for advanced prostate cancer goes to first clinical trial

A drug candidate developed by researchers at the University of Tennessee Health Science Center for advanced metastatic castration-resistant prostate cancer is now in its first clinical trial.

6 Nov 2023

TIMP2 protein identified as key player in brain plasticity and memory

Researchers explored the molecular and cellular processes regulated by tissue inhibitor of metalloproteinases-2 (TIMP2) in the extracellular matrix (ECM) of the adult brain hippocampus.

6 Nov 2023

Sparsentan may be a new treatment option for focal segmental glomerulosclerosis

Focal segmental glomerulosclerosis (FSGS) is a rare kidney disorder that affects children and adults, and can lead to kidney failure.

3 Nov 2023

New prediction model estimates risk of opioid relapse early in treatment

A newly developed prediction model may be able to calculate the risk of opioid relapse among individuals in the early stages of medication treatment - as early as three weeks into therapy.

3 Nov 2023

High-impact clinical trial results to be presented at ASN Kidney Week 2023

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2023 November 1–November 5.

3 Nov 2023

Marijuana-like compound shows promise as new treatment for skin lupus

A marijuana-like compound holds out promise as a new treatment for a severe autoimmune skin disease called skin lupus, according to a study published recently by a multicenter team including researchers at the George Washington University.

2 Nov 2023

LHPP gene identified as a potential target for treatment-resistant depression

Major depressive disorder (MDD) is a widespread mental health condition that for many is disabling. It has long been appreciated that MDD has genetic as well as environmental influences.

2 Nov 2023

Bridging Chemistry and Biology: The Art of Designing Novel Therapeutics

In this interview, we delve into the journey and research of Sona Krajcovicova, exploring how diverse interests led to a passionate pursuit of chemistry, innovative approaches to drug development, and a commitment to making a meaningful impact on the world of therapeutics.

From ELRIG (UK) Ltd. 2 Nov 2023

Existing drug could be repurposed to treat type 1 diabetes, study suggests

Type 1 diabetes is an autoimmune disease that causes the body's immune system to attack and destroy insulin-producing beta cells in the pancreas. Traditional management of type 1 diabetes has primarily involved replacing the missing insulin with injections which, though effective, can be expensive and burdensome.

1 Nov 2023

Repurposing of DFMO could lead to innovative therapies for type 1 diabetes

A recent study led by Indiana University School of Medicine in collaboration with the University of Chicago Medicine presents exciting future possibilities for the management of type 1 diabetes and the potential reduction of insulin dependency.

1 Nov 2023

Clinical trial demonstrates the effectiveness of ALS drug in treating people with acute spinal cord injuries

A small clinical trial with a pharmacokinetic sub-study, led by a world-renowned pharmacologist at the University of Houston, has demonstrated the promising effectiveness of the drug Riluzole for improving functionality in people with acute spinal cord injuries (SCI) if the drug is taken within 12 hours post-injury.

1 Nov 2023

New drug shows promise in killing cancer cells with genetic vulnerability

Imagine the body's cells are well-behaved students in the classroom. The "teachers" are tumor suppressor genes, and they make sure cells follow the rules. But when tumor suppressor genes are away, cells may go astray.

1 Nov 2023

New gene editing method creates first mice with human-like COVID-19

Researchers have genetically engineered the first mice that get a human-like form of COVID-19, according to a study published online November 1 in Nature.

1 Nov 2023

New AI tool could lead to precision medicine by predicting drug response

An ideal medicine for one person may prove ineffective or harmful for someone else, and predicting who could benefit from a given drug has been difficult.

31 Oct 2023

UniSA seeks public support for vital research on deadly brain cancers

The University of South Australia is seeking public support for vital brain cancer research that could potentially save hundreds of lives.

31 Oct 2023

Promising new drug target for triple-negative breast cancer identified

Improving treatments for triple-negative breast cancer (TNBC), an aggressive tumor with very poor prognosis and limited therapeutic targets, has been challenging.

30 Oct 2023

New MECP2 gene variant identified and characterized in Rett syndrome

Rett syndrome is a rare devastating neurological disorder that primarily affects young girls and manifests as an impaired ability to walk and talk, along with characteristic 'hand-wringing' movements, seizures, and cognitive disability.

30 Oct 2023

Redefining the battle against Alzheimer's with tau-focused treatments

Researchers explore the potential of tau-targeting therapies in treating Alzheimer's disease, focusing on immunotherapies and strategies to improve their efficacy. The study dives into the complex biology of tau proteins, their modifications, and how they can be targeted to halt the progression of Alzheimer's.

29 Oct 2023

Eppendorf & Science Prize for Neurobiology awarded to Marissa Scavuzzo for glial cell research

Marissa Scavuzzo, a postdoctoral fellow at the Case Western Reserve University School of Medicine, has won the 2023 Eppendorf & Science Prize for Neurobiology for research in how glial cells in the intestine's nervous system operate.

27 Oct 2023

New treatment combination shows promise for metastatic colorectal cancer patients with rare genetic mutation

An international Phase 3 clinical trial found that metastatic colorectal cancer patients with a rare genetic tumor mutation called KRAS G12C experienced superior progression-free survival rates compared to standard of care when offered a combination treatment of KRAS inhibitor sotorasib and monoclonal antibody panitumumab.

27 Oct 2023